Alamar Biosciences Launches NULISAseq Immune 340 Panel
FREMONT, Calif., July 28, 2026 Alamar Biosciences, Inc. has announced the commercial launch of the NULISAseqâ„¢ Immune 340 Panel,...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
FREMONT, Calif., July 28, 2026 Alamar Biosciences, Inc. has announced the commercial launch of the NULISAseqâ„¢ Immune 340 Panel,...
FREMONT, California, July 13, 2026 Alamar Biosciences has partnered with leading U.S. research universities to launch a national-scale proteomics...
MARLBOROUGH, Mass., June 1, 2026 SCIEX, a Danaher company and a global leader in life science analytical technologies, announced...
SOUTH SAN FRANCISCO, California, May 27, 2026 Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation...
SAN DIEGO, Calif., April 28, 2026 Sapient has announced the launch of its Tumor Protein Mapping Platform, a next-generation...
ST. PAUL, Minn., April 23, 2026 Astrin Biosciences announced that it has received accreditation from the College of American...
Fremont, California, March 17, 2026 Alamar Biosciences, Inc. announced the launch of its NULISAseqâ„¢ Neuro 220 Panel, a next-generation...
BEND, Oregon | January 8, 2026 — Arrayjet, a provider of high-throughput microarray printing technologies, has opened its first...
